- Home
- AGIO vs BWLP Comparison
AGIO vs BWLP Comparison
Compare AGIO & BWLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BWLP
- Stock Information
- Founded
- AGIO 2007
- BWLP 1935
- Country
- AGIO United States
- BWLP Singapore
- Employees
- AGIO N/A
- BWLP N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BWLP Marine Transportation
- Sector
- AGIO Health Care
- BWLP Consumer Discretionary
- Exchange
- AGIO Nasdaq
- BWLP Nasdaq
- Market Cap
- AGIO 1.4B
- BWLP 1.6B
- IPO Year
- AGIO 2013
- BWLP N/A
- Fundamental
- Price
- AGIO $35.00
- BWLP $13.23
- Analyst Decision
- AGIO Buy
- BWLP
- Analyst Count
- AGIO 6
- BWLP 0
- Target Price
- AGIO $57.40
- BWLP N/A
- AVG Volume (30 Days)
- AGIO 840.6K
- BWLP 344.2K
- Earning Date
- AGIO 07-31-2025
- BWLP 08-27-2025
- Dividend Yield
- AGIO N/A
- BWLP 12.83%
- EPS Growth
- AGIO N/A
- BWLP N/A
- EPS
- AGIO 11.13
- BWLP 1.86
- Revenue
- AGIO $40,875,000.00
- BWLP $3,387,328,000.00
- Revenue This Year
- AGIO $18.94
- BWLP N/A
- Revenue Next Year
- AGIO $201.70
- BWLP N/A
- P/E Ratio
- AGIO $3.15
- BWLP $7.72
- Revenue Growth
- AGIO 30.57
- BWLP 9.53
- 52 Week Low
- AGIO $23.42
- BWLP $7.86
- 52 Week High
- AGIO $62.58
- BWLP $16.82
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- BWLP 54.65
- Support Level
- AGIO $37.09
- BWLP $13.26
- Resistance Level
- AGIO $39.12
- BWLP $14.05
- Average True Range (ATR)
- AGIO 1.78
- BWLP 0.24
- MACD
- AGIO -0.67
- BWLP -0.06
- Stochastic Oscillator
- AGIO 9.16
- BWLP 39.93
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.